Abstract
HTA172 Value of French Framework for Early Access Programs for the HTA Appraisal in the Rare Disease Space: The Example of Lanadelumab in Patients With Hereditary Angioedema
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
